Royalty Pharma (RPRX) Debt Ratio (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Debt Ratio data on file, last reported at 0.47 in Q1 2026.

• For the quarter ending Q1 2026, Debt Ratio rose 8.91% year-over-year to 0.47; the trailing twelve-month figure through Mar 2026 stood at 0.47 (up 8.91% YoY), and the FY2025 full-year result was 0.48, up 0.65% from the prior year.
• Debt Ratio declined to 0.47 in Q1 2026, from 0.48 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.48 in Q1 2023 to a low of 0.37 in Q4 2023.
• A 5-year average of 0.43 and a median of 0.43 in 2024 frame the typical range for Debt Ratio.
• Peak annual rise in Debt Ratio reached 26.16% in 2024, while the deepest fall reached 19.97% in 2024.
• Tracing RPRX's Debt Ratio over 5 years: stood at 0.42 in 2022, then fell by 11.51% to 0.37 in 2023, then climbed by 26.16% to 0.47 in 2024, then climbed by 0.65% to 0.48 in 2025, then dropped by 0.92% to 0.47 in 2026.
• Business Quant data shows RPRX's Debt Ratio at 0.47 in Q1 2026, 0.48 in Q4 2025, and 0.46 in Q3 2025.